论文部分内容阅读
目的回顾性观察左西孟旦治疗扩张型心肌病(DCM)心衰患者生存质量情况,及超声心动图下心脏重构和心功能的变化情况。方法入选DCM且心功能Ⅲ~Ⅳ级(NYHA分级)的患者,随机分为左西孟旦治疗组和对照组,入院及随访时填写SF-36生存质量调查表并行超声心动图检查心脏结构和功能。结果用药组患者在治疗后1个月和3个月时的生存质量评分高于对照组。心脏彩超显示两组治疗后射血分数无明显改善,但用药组治疗后房室内径缩小。结论对DCM心衰患者应用左西孟旦可显著提高3个月内的生存质量,延缓6个月内心脏重构进程,但无法明显逆转心脏重构及改善心功能。
Objective To retrospectively observe the quality of life of patients with left heart failure treated with dilated cardiomyopathy (DCM) and the cardiac remodeling and cardiac function under echocardiography. Methods Patients with DCM and NYHA class Ⅲ were randomly divided into levosimendan treatment group and control group. At the time of admission and follow-up, SF-36 quality of life questionnaire was completed and echocardiography was performed to check the cardiac structure and Features. Results The quality of life of the patients in the medication group at 1 month and 3 months after treatment was higher than that of the control group. Echocardiography showed no significant improvement in ejection fraction after treatment in both groups, but the atrioventricular diameter decreased after treatment in the treatment group. Conclusion The application of levosimendan in patients with heart failure can significantly improve the quality of life within 3 months, delay the process of cardiac remodeling within 6 months, but can not significantly reverse cardiac remodeling and improve cardiac function.